Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effisayil ON long-term extension in generalized pustular psoriasis
2023-509216-28-00Phase 2Authorised
- Sponsor
- LEO Pharma
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by LEO Pharma. Primary endpoint: Treatment-emergent adverse events. Planned start May 2019; status: authorised.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on 2023-509216-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509216-28-00.